Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MelCancerVac
- Development stage
- Phase 2
- Lead developer
- DanDrit Biotech
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal (based On Standard Practice For Dendritic Cell Vaccines; Specific Route Not Explicitly Stated In Sources But Inferred From Clinical Context)
01
Overview
MelCancerVac is a dendritic cell-based therapeutic cancer vaccine developed for the treatment of various solid tumors, including metastatic colorectal cancer, breast cancer, advanced colorectal adenocarcinoma, and melanoma. The vaccine utilizes autologous dendritic cells loaded with tumor antigens to stimulate the patient's immune system toward a Th1-dominated response against tumor cells. Clinical studies have shown that the vaccine is non-toxic and safe, with some patients achieving stable disease and maintaining high quality of life during treatment. Immunological analyses indicate increased levels of Th1 cytokines (such as GM-CSF, TNF-alpha, IFN-gamma, IL-2) in patients who respond to therapy[1][2].
- Brand names
- MelCancerVac
- Other names
- MelCancerVac
Beyond the preview
Go deeper on MelCancerVac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MelCancerVac.